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Abstract
Background: Growing evidence suggests that alterations of the inflammatory/immune system contribute to the
pathogenesis of depression. Indeed, depressed patients exhibit increased levels of inflammatory markers in both the
periphery and the brain, and high comorbidity exists between major depression and diseases associated with
inflammatory alterations. In order to characterize the link between depression and inflammation, we aimed to
investigate whether an altered inflammatory system is present in a genetic model of vulnerability for depression,
namely rats with partial or total deletion of the serotonin transporter (SERT) gene.
Methods: Wild-type, heterozygous and homozygous SERT rats were analyzed under basal condition or following a
challenge with an acute injection of lipopolysaccharide (LPS) and killed 24 h or 5 days later.
Results: We found that SERT mutant rats show altered cytokine expression in the dorsal and ventral hippocampus
at basal conditions, and they also display an exacerbated cytokine response to the LPS challenge. Moreover, mutant
rats exhibit differences in the expression of markers for microglia activation.
Conclusion: Based on these data, we suggest that basal or functional alterations of immune/inflammatory systems
might contribute to the phenotype of SERT rats and to their heightened susceptibility to depressive-like behavior.
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Background
Major depressive disorder (MDD) is a leading cause of
disability in the world supposedly originating from the
interaction between a background of genetic vulnerabil-
ity and adverse environmental factors. Compelling evi-
dence also suggests that inflammation may contribute
to specific dysfunctions associated with depression [1,2].
Accordingly, depression shows elevated comorbidity with
immune-related diseases such as cancer, cardiovascular
and neurodegenerative diseases that are characterized by
the presence of inflammatory alterations [3,4]. In addition,
depressed patients exhibit all the cardinal features of in-
flammation [5]. Indeed, elevated blood levels of the
proinflammatory cytokines, including interleukin (IL)-1β,
IL-6 and tumor necrosis factor (TNF)-α, are commonly
found in depressive subjects [6-9]. It has also been shown
that depressed suicidal attempters display elevated levels of
IL-6 in the cerebrospinal fluid [10]. Moreover, it has been
demonstrated that IL-6 is related to the stress-induced de-
velopment of depression-like behaviors in mice [11].
Furthermore, the endotoxin lipopolysaccharide (LPS),
a proinflammatory agent, can trigger the development of
depressive symptoms in humans as well as depressive-
related behavior in rodents [1,12-14]. In line with this,
patients treated with interferons and interleukins often
develop depression [15]. This evidence suggests that
immune-inflammatory signals may represent an ‘en-
vironmental’ condition relevant for the etiology of mood
disorders, which may also unmask a latent genetic
vulnerability.
In this respect, one of the most extensively investi-
gated susceptibility genes in depression encodes for the
serotonin transporter (5-HTT or SERT), which is respon-
sible for the re-uptake of serotonin into the presynaptic
terminal [16]. The 5-HTT gene exists in two major allelic
variants, a long (L) form and a short (S) form. It has been
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demonstrated that the S variant leads to reduced ex-
pression of the transporter [17] and might enhance the
sensitivity to the pro-depressive effects of stressful life
events in rhesus monkeys [18] as well as in humans
[19,20]. Furthermore, SERT knockout mice [21-23], as
well as SERT mutant rats [24], show depression and
anxiety-related behaviors, as well as impaired neuronal
plasticity [25-27], supporting the possibility that altered
function of SERT may be associated with increased risk
of mood disorders [28]. Interestingly, it has been re-
cently shown that the short variant of SERT is also as-
sociated with higher risk of developing depression in
patients following INF-α treatment [29].
Based on these observations, the purpose of the pre-
sent study was twofold. First, we established whether
partial or total deletion of the SERT gene is associated
with altered expression of inflammatory markers in basal
conditions. Next, in order to establish whether genetic
susceptibility to depression is associated with significant
changes in the inflammatory/immune system, we inves-
tigated whether SERT heterozygous rats show altered re-
sponsiveness to an inflammatory challenge with LPS.
We chose SERT+/− animals since the partial SERT dele-
tion better mimics the condition of humans carrying the
short variant of the 5-HTTLPR, which has been associ-
ated with enhanced susceptibility to environmental ad-
versities [30]. The higher validity of SERT heterozygous
models has already been discussed [31,32], and the be-
havioral vulnerability of SERT heterozygous animals has
been previously demonstrated for mice [21,33].
Methods
General reagents were purchased from Sigma-Aldrich
(Milan, Italy), and molecular biology reagents were ob-
tained from Applied Biosystem Italia (Monza, Italy),
Eurofins MWG-Operon (Ebersberg, Germany) and Bio-
Rad Laboratories S.r.l. (Segrate, Italy). Lipopolysaccharide
(from Escherichia coli 026:B6 ≥10,000 eu/mg) was pur-
chased from Sigma-Aldrich (code L8274).
Animals and experimental paradigm
Serotonin transporter knockout rats (Slc6a41Hubr) were
generated in a Wistar background by N-ethyl-N-nitrosurea
(ENU)-induced mutagenesis [34]. Experimental animals
were derived from crossing heterozygous SERT knockout
rats that were out crossed for at least ten generations with
wild-type Wistar rats obtained from Harlan Laboratories.
All subjects were bred and reared in the Central Animal
Laboratory of the University of Nijmegen. After weaning
at the age of 21 days, ear cuts were taken for genotyping.
In all experiments, adult male SERT+/+(WT), SERT+/−
and SERT−/− rats were used. Animals were housed in
groups of four per cage under standard conditions (12-h
light/dark cycle with food and water ad libitum) and
were exposed to daily handling for 1 week before any
treatment.
Rats were randomly divided into two experimental
groups: control (39 rats) and treated animals (40 rats);
the first group received saline, whereas the second one
was treated with a single injection of lipopolysaccharide
(250 μg/Kg, i.p.). They were killed 1 or 5 days later. Our
analyses were carried out in the ventral and dorsal hip-
pocampus, which were rapidly dissected, frozen on dry
ice and stored at −80°C for molecular analyses.
All experiments were approved by the Committee for
Animal Experiments of the Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands, and all efforts
were made to minimize animal suffering and to reduce the
number of animals used in accordance with the Guidelines
laid down by the European Communities Council Directive
of 24 November 1986 (86/609/EEC).
Protein analysis of plasma inflammatory mediators
Samples of blood from each rat were collected in hepa-
rinized tubes. Plasma was separated by centrifugation
(5,000 rpm for 10 min at 4°C), and interleukin (IL)-6,
tumor necrosis factor (TNF)-α, cytokine-induced neu-
trophil chemoattractant (CINC)-1, CINC-3 and macro-
phage inflammatory protein (MIP)-1α protein levels
were quantified using a Rat Cytokine Array kit (R&D
Systems, Inc.) according to the manufacturer’s instructions.
Briefly, plasma was diluted and mixed with a cocktail of
biotinylated detection antibodies. The sample/antibody
mixture was then incubated with the rat cytokine array
membrane where capture and control antibodies have
been spotted. Any cytokine/detection antibody complex
present was bound by its cognate immobilized capture
antibody on the membrane. Following a wash to remove
unbound material, streptavidin-HRP and chemilumines-
cent detection reagents were applied and a signal was
produced at each spot corresponding to the amount of
cytokine bound. Protein levels were calculated by measur-
ing the optical density of the autoradiographic bands using
Quantity One software (Bio-Rad Laboratories). To ensure
that autoradiographic bands were in the linear range of in-
tensity, different exposure times were used.
RNA preparation and gene expression analyses
For gene expression analysis, total RNA was isolated from
the different brain regions by single-step guanidinium iso-
thiocyanate/phenol extraction using the PureZol RNA iso-
lation reagent (Bio-Rad Laboratories S.r.l.; Segrate, Italy)
according to the manufacturer’s instructions and quanti-
fied by spectrophotometric analysis. The samples were
then processed for real-time polymerase chain reaction
(PCR) as previously reported [35] to assess levels of inter-
leukin 1β (IL-1β) interleukin-6 (IL-6), integrin alpha M
(cluster of differentiation molecule CD11b), chemokine
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(C-X3-C motif ) ligand 1 (CX3CL1; fractalkine) and
integrin-associated protein (CD47).
Briefly, an aliquot of each sample was treated with
DNase to avoid DNA contamination and subsequently
analyzed by the TaqMan qRT-PCR instrument (CFX384
real-time system, Bio-Rad Laboratories S.r.l.) using the
iScript one-step RT-PCR kit for probes (Bio-Rad Labora-
tories S.r.l.). Samples were run in 384-well format in tripli-
cate as multiplexed reactions with a normalizing internal
control (β-actin). Thermal cycling was initiated with incu-
bation at 50°C for 10 min (RNA retrotranscription) and
then at 95°C for 5 min (TaqMan polymerase activation).
After this initial step, 39 cycles of PCR were performed.
Each PCR cycle consisted of heating the samples at 95°C
for 10 s to enable the melting process, and then for 30 s at
60°C for the annealing and extension reactions. A com-
parative cycle threshold (Ct) method was used to calculate
the relative target gene expression. Probe and primer
sequences used were purchased from Applied Biosystem
Italia and Eurofins MWG-Operon.
Statistical analyses
The effect of the genotype on gene expression was ana-
lyzed with a one-way analysis of variance (ANOVA),
followed by Fisher’s protected least significant difference
(Fisher PLSD), whereas the effect of the LPS was ana-
lyzed with a two-way ANOVA with genotype (WT vs.
SERT+/− rats) and treatment (Sal vs. LPS) as independ-
ent factors and mRNA levels as dependent variable.
When appropriate, further differences were analyzed by
single contrast post hoc test (SCPHT). Significance for
all tests was assumed at P < 0.05. Data are presented as
means ± standard error (SEM). For graphic clarity, re-
sults are presented as mean percent of WT rats (basal
effect analysis) and WT or SERT+/− rats treated with sa-
line (LPS effect analysis).
Results
We first analyzed different markers of the immune sys-
tem at the peripheral level of SERT+/− and SERT−/− ani-
mals. Specifically, we measured the protein level of two
cytokines, IL-6 and TNF-α and CINC-1, CINC-3 and
MIP-1α, which belong to the family of chemokines. As
shown in Table 1, all these markers were strongly up-
regulated in the plasma of SERT−/− rats, whereas we did
not find any change in SERT heterozygous animals.
On these bases, we decided to analyze the expression
levels of inflammatory markers in the hippocampus of
mutant rats under resting conditions or following an
acute challenge with LPS. We chose to investigate this
brain area because it is highly relevant for depression
and it is also vulnerable to environmental challenges
[36-38]. Moreover, we decided to compare the ventral and
dorsal part of the hippocampus since the two subregions
subserve different functions. In particular, the dorsal part
(DH) has been linked to cognition, whereas the ventral
portion (VH) has been associated with emotion and stress
responses [39].
IL-1β expression
We first measured IL-1β mRNA and, as shown in
Figure 1, we found that under basal conditions the expres-
sion of IL-1β was significantly increased in the dorsal
hippocampus (A) of SERT+/− and SERT−/− animals (+55%,
P < 0.001; +37%, P < 0.05 respectively), whereas, in the ven-
tral hippocampus, (B) the cytokine mRNA levels were in-
creased only in rats with partial deletion of the gene
(+68%, P < 0.01). Next, we investigated the responsiveness
of SERT+/− rats to a challenge with the proinflammatory
agent LPS. The analyses were carried out only in SERT+/−
rats, which more closely mimic the genetic vulnerability as-
sociated with patients carrying the S variant of the 5-HTT
gene. In the dorsal hippocampus (Figure 1C), we found
that LPS produced similar changes in both genotypes. In-
deed, the mRNA levels for IL-1β were significantly in-
creased 1 day after LPS injection in WT (+634%, P < 0.01)
as well as in SERT+/− rats (+513%, P < 0.05), but not
after 5 days when the cytokine expression levels had
returned to control levels. Conversely, in the ventral
hippocampus (Figure 1D), LPS injection produced larger
changes in SERT+/− rats since IL-1β upregulation at
24 h was more pronounced in mutant animals (+964%
vs. +370% in WT rats) and also persisted up to 5 days
after the proinflammatory challenge (+156%, P < 0.05)
when the cytokine expression had returned to control
levels in wild-type rats.
IL-6 expression
Unlike what we observed for IL-1β, the mRNA levels of
IL-6 (Figure 2) were not significantly altered under basal
conditions in the dorsal (A) or ventral hippocampus (B)
of SERT mutant rats. However, we found that the SERT
genotype had a significant effect on the modulation of
Table 1 Protein analysis of inflammatory mediators in the
plasma of SERT mutant rats
Gene SERT +/− SERT −/−
CINC-1 = +
CINC-3 = +++
MIP-1α = +++
IL-6 = ++
TNF-α = +
The table shows the changes of interleukin 6 (IL-6), tumor necrosis factors
(TNF-α), cytokine-induced neutrophil chemoattractant 1 (CINC-1), cytokine-
induced neutrophil chemoattractant 3 (CINC-3) and macrophage inflammatory
protein (MIP-1α) found in SERT mutant as compared to wild-type animals. =,
no change; +, 5- to 10-fold increase; ++ 20- to 30-fold increase; +++ more
than 30-fold increase.
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IL-6 gene expression after LPS challenge. In the dorsal
hippocampus (Figure 2C), 24 h after LPS injection, IL-6
mRNA levels were significantly increased in SERT+/−
(+136%, P < 0.001) but not wild-type animals (+58%,
P = 0.067), whereas the cytokine expression was back to
control levels in both genotypes 5 days post-LPS. A similar
profile was found in the ventral hippocampus (Figure 2D),
since IL-6 expression was upregulated 24 h post LPS ad-
ministration in SERT+/− (+58%, P < 0.01) but not in WT
rats (−11%, P = 0.565). Also in this brain region, no signifi-
cant changes of IL-6 mRNA levels were found 5 days after
LPS challenge in both genotypes.
CD11b expression
Besides cytokine production, another important aspect
of the inflammatory response is microglia activation
[40]. In order to evaluate if the basal activity of microglia
was altered as a consequence of SERT gene deletion, we
assessed the expression of CD11b, a marker for this cel-
lular phenotype [41]. As shown in Figure 3A, we found
that the basal expression of CD11b was significantly higher
in dorsal hippocampus of SERT+/− (+56%, P < 0.05) but not
in SERT−/− rats. A similar change was also observed in the
ventral hippocampus (Figure 3B) where the expression of
the microglial marker was significantly upregulated under
basal conditions in SERT+/− (+120%, P < 0.01) as well as in
SERT−/− rats (+173%, P < 0.001).
Next, we examined CD11b mRNA levels following
the acute LPS challenge. In the dorsal hippocampus
(Figure 3C), the mRNA levels of CD11b were significantly
increased 1 day after LPS treatment in WT (+312%,
P < 0.001) as well as in SERT+/− rats (+274%, P < 0.001),
while its expression returned to basal levels in both geno-
types 5 days post-LPS. In the ventral hippocampus
(Figure 3D), we found a significant increase of CD11b
mRNA levels 24 h after LPS injection in WT (+436%,
P < 0.001) and SERT+/− rats (+332%, P < 0.001). How-
ever, 5 days after LPS challenge the mRNA levels of
CD11b were upregulated in WT rats (140%, P < 0.001),
but they had returned to baseline in SERT+/− rats.
Figure 1 Analysis of interleukin (IL)-1β gene expression in the hippocampus of SERT mutant rats. Basal expression of IL-1β mRNA levels
were measured in dorsal (A) and ventral (B) hippocampus of mutant rats. The data, expressed as percentage of SERT+/+ (wild-type) animals
(set at 100%), are the mean ± SEM of at least five independent determinations. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. SERT+/+ (one-way
ANOVA with SCPHT). The expression of IL-1β was also investigated in dorsal (C) and ventral (D) hippocampus following an acute LPS challenge,
the animals being killed 1 or 5 days after the immune challenge. The data are expressed as percentage of the respective saline-injected counterpart
(set at 100%, dashed line) and represent the mean ± SEM of at least five independent determinations. #P < 0.05, ##P < 0.01, ###P < 0.001 vs. control
(one-way ANOVA with SCPHT).
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CX3CL1 and CD47 expression
In order to gain further insight into the changes of micro-
glial function, we investigated the glia-neuron cross-talk.
Indeed, microglial function may be controlled through sig-
nals that keep it in a resting state or that may favor its acti-
vation [42]. In this respect, the interactions between
fractalkine (CX3CL1) and CD47 with their receptors play a
crucial role in maintaining microglia in a resting state [43].
Therefore, we analyzed the expression of CX3CL1 and
CD47 in the dorsal and ventral hippocampus of SERT+/−
and wild-type animals.
As shown in Figure 4A, the expression of CX3CL1
was not altered in the dorsal hippocampus of SERT+/−
rats under basal conditions, while its mRNA levels were
increased in the ventral subregion of mutant rats (+36%,
P < 0.001).
When considering the inflammatory challenge, CX3CL1
mRNA levels were not altered in the dorsal hippo-
campus of WT rats 24 h after LPS treatment (Figure 4C),
while they were significantly increased in SERT+/−
animals (+42%, P < 0.001). Conversely, 5 days after
the LPS challenge, the expression of CX3CL1 was signifi-
cantly reduced in both genotypes (WT: -19%, P < 0.05;
SERT+/−: -20%, P < 0.05). In the ventral hippocampus
(Figure 4D), the mRNA levels of CX3CL1 were up-
regulated 1 day after LPS injection in WT rats (+144%,
P < 0.001), but not in SERT+/− animals, whereas no signifi-
cant changes were observed 5 days post-LPS challenge.
Conversely, as shown in Figure 5, basal expression of
CD47 was reduced in the dorsal hippocampus of SERT+/−
rats (−34%, P < 0.01), while it was increased in the ventral
hippocampus (+144%, P < 0.001). Following LPS challenge,
the expression of CD47 was not altered in the dorsal
hippocampus of WT rats 24 h post-injection, and it was re-
duced 5 days after (−23%, P < 0.05), (Figure 5C). Con-
versely, the expression of CD47 was decreased at 24 h
post-LPS in SERT+/− animals (−30%, P < 0.05), but was sig-
nificantly upregulated 5 days post-LPS injection (+30%,
P < 0.05). In the ventral hippocampus (Figure 5D), the
mRNA levels of CD47 were upregulated 1 day after
LPS administration in WT rats (+99%, P < 0.001) but
not in SERT+/− animals. On the contrary, 5 days after the
Figure 2 Analysis of interleukin (IL)-6 gene expression in the hippocampus of SERT mutant rats. Basal interleukin (IL)-6 gene expression is
not altered in dorsal (A) or ventral (B) hippocampus of mutant rats. The data, expressed as percentage of SERT+/+ (wild-type) animals (set at 100%),
are the mean ± SEM of at least five independent determinations. The expression of IL-6 is upregulated in both dorsal (C) and ventral (D) hippocampus
only in SERT+/− animals 1 day after an lipopolysaccharide (LPS) challenge. The data are expressed as percentage of the respective saline-injected
counterpart (set at 100%, dashed line) and represent the mean ± SEM of at least five independent determinations. ##P< 0.01, ###P < 0.001 vs. control
(one-way ANOVA with SCPHT).
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inflammatory challenge the expression of the microglial
marker had returned to control values in WT rats,
while being significantly increased in SERT mutant
rats (+29%, P < 0.05).
Discussion
Our results suggest that genetic deletion of the sero-
tonin transporter in rats is associated with alterations of
immune/inflammatory players, such as proinflammatory
cytokines and markers of microglia activation, under basal
conditions or following an immune challenge. These re-
sults support the idea of a close and reciprocal modulation
between a gene strongly associated with depression and
systems involved in the immune response, in line with the
idea that inflammation represents an important environ-
mental factor for depression susceptibility [1,44,45]. In-
deed, we demonstrate that animals with partial or total
deletion of the SERT gene have, under basal conditions,
enhanced levels of circulating immune proteins as well as
increased expression of IL-1β in dorsal and ventral hippo-
campus. In this respect, it is interesting to notice that
major changes occurred in heterozygous animals, which
mimic more closely the human situation of individuals car-
rying the short (S) variant of the SERT gene that is associ-
ated with enhanced vulnerability to depressive disorders
[19,20]. Besides this, Su and colleagues have demonstrated
that in S-carrier subjects depressive symptoms are associ-
ated with elevated plasma levels of IL-6 [46]. Moreover,
healthy SS carriers of the serotonin transporter show, when
compared to LL carriers, a proinflammatory phenotype,
measured as the ratio between IL-6 and IL-10, under
resting conditions as well as following an acute stress
[47]. These data are in good agreement with the results
of our study, also in respect to the responsiveness to an
immune challenge. In particular, while cytokine mRNA
levels are similarly increased in the dorsal hippocam-
pus of all genotypes, the response to LPS was exacer-
bated in the ventral hippocampus of SERT+/− rats,
where the cytokine upregulation was not only quantita-
tively larger but also lasted up to 5 days after the in-
flammatory challenge. The anatomical specificity is in line
with the potential role of these changes for depression
Figure 3 Analysis of integrin alpha M (CD11b) gene expression in the hippocampus of SERT mutant rats. Basal CD11b gene expression is
altered in dorsal (A) and ventral (B) hippocampus of mutant rats. The data, expressed as percentage of SERT+/+ animals (set at 100%), are the
mean ± SEM of at least five independent determinations. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. SERT+/+ (one-way ANOVA with SCPHT). The
expression of CD11b is upregulated in dorsal (C) and ventral (D) hippocampus of WT or SERT+/− animals 1 or 5 days after an LPS challenge. The
data are expressed as percentage of the respective saline-injected counterpart (set at 100%, dashed line) and represent the mean ± SEM of at least
five independent determinations. ##P < 0.01, ###P < 0.001 vs. control (one-way ANOVA with SCPHT).
Macchi et al. Journal of Neuroinflammation 2013, 10:116 Page 6 of 10
http://www.jneuroinflammation.com/content/10/1/116
considering that the ventral subregion of the hippo-
campus is primarily involved in emotional responses
and stress regulation [48].
One key element of the inflammatory response is the
activation and modulation of microglia [40]. These cere-
bral immune cells are normally present in the healthy
brain where they actively survey the system and may
rapidly respond to any microenvironment alteration [49].
To substantiate the phenotype of SERT mutant rats, we
found increased mRNA levels of CD11b in the ventral and
dorsal hippocampus. In particular, SERT+/− rats displayed
more obvious alterations, suggesting once again that het-
erozygous rats are more sensitive to an LPS challenge.
Indeed, we observed a genotype-dependent increase in
CD11b: after 24 h from LPS administration there was no
difference, whereas after 5 days microglia was still activated
in wild-type but not in SERT+/− animals. The inter-
pretation of these results is not straightforward, since
the mechanisms underlying microglia activation and
its functional consequences are not completely under-
stood. Indeed, microglia is considered to function as a
double-edged sword since its response is not necessarily
neurotoxic, but may be useful to control and clear
damage resulting from challenging conditions [42]. In
line with these considerations, our results suggest that
SERT mutant rats show activated microglia under basal
conditions, which may eventually be associated with
a chronic inflammatory state, also suggested by in-
creased expression of proinflammatory cytokines. On
the other hand, the microglial response to the inflamma-
tory challenge is largely similar in SERT wild-type and
mutant rats, suggesting that the intensity of the challenge
may not be adequate for discriminating between the two
cohorts.
Microglia is maintained in a resting state through
neuron-derived signals including CX3CL1 and CD47,
which act on their respective receptors CX3CR1 and
CD172A expressed by microglia [42,50,51]. However,
according to our data, the activation of microglia ob-
served in mutant rats under basal condition cannot be
explained by changes in the expression of CX3CL1 and
CD47, as their mRNA levels are even higher in the ventral
Figure 4 Analysis of chemokine ligand 1 (CX3CL1) gene expression in the hippocampus of SERT mutant rats. Basal CX3CL1 gene
expression is altered in the ventral hippocampus of mutant rats (B) but not in the dorsal hippocampus (A). The data, expressed as percentage of
SERT+/+ animals (set at 100%), are the mean ± SEM of at least five independent determinations. ***P < 0.001 vs. SERT+/+ (one-way ANOVA with
SCPHT). The expression of CX3CL1 is modulated in dorsal (C) and ventral (D) hippocampus of WT or SERT+/− animals 1 or 5 days after an LPS
challenge. The data are expressed as percentage of the respective saline-injected counterpart (set at 100%, dashed line) and represent the mean ± SEM of
at least five independent determinations. #P< 0.5, ###P< 0.001 vs. control (one-way ANOVA with SCPHT).
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hippocampus of SERT+/− rats. We may speculate that
the basal upregulation of these genes may represent a
compensatory mechanism aimed at limiting the micro-
glial activation observed in SERT mutant rats under
basal conditions. In line with this interpretation, 24 h
after the LPS challenge CX3CL1 and CD47 mRNA levels
were markedly increased in wild-type animals but not in
mutant rats, further suggesting a dysregulation of the
mechanisms responsible for the control of microglial func-
tion and activation.
Multiple molecular mechanisms may be involved in
the differential inflammatory response observed after
LPS challenge in SERT mutant rats. For example, it is
known that LPS can activate and recruit Toll-like recep-
tors (TLRs), especially TLR4, which appear important in
mood-related disorders [52]. However, since hippocam-
pal TLR4 gene expression is not altered in SERT mutant
rats (data not shown), other mechanism may be respon-
sible for heightened responsiveness to LPS challenge of
SERT+/− rats.
In conclusion, our results demonstrate that the inflam-
matory/immune system is altered in rats with genetic al-
terations of the serotonin transporter. Moreover, these
animals show a different response to an inflammatory
challenge, suggesting that some of the mechanisms that
regulate these systems can be compromised, thus render-
ing the hippocampus more susceptible to the adverse
influence of inflammatory mediators. Since depression
vulnerability can be associated with increased inflamma-
tion, we suggest that the alterations of the immune system
observed in animals with a deletion of the SERT gene may
contribute to their pathologic phenotype. Furthermore,
considering that depressed patients with higher levels of
cytokines, as well as individuals carrying the S variant of
the 5-HTTLPR polymorphism, are less responsive to anti-
depressant treatment [53,54], we may speculate that alter-
ations of the immune/inflammatory system in depressed
individuals may not only contribute to the pathologic
phenotype, but also represent an important component for
the response to pharmacological intervention.
Figure 5 Analysis of integrin-associated protein (CD47) gene expression in the hippocampus of SERT mutant rats. Basal CD47 mRNA
levels are decreased in the dorsal hippocampus (A) of SERT+/− rats, while they are increased in the ventral hippocampus (B). The data,
expressed as percentage of SERT+/+ animals (set at 100%), are the mean ± SEM of at least five independent determinations. **P < 0.01 and
***P < 0.001 vs. SERT+/+ (one-way ANOVA with SCPHT). The expression of CD47 is modulated in dorsal (C) and ventral (D) hippocampus of
WT or SERT+/− animals 1 or 5 days after an LPS challenge. The data are expressed as percentage of the respective saline-injected
counterpart (set at 100%, dashed line) and represent the mean ± SEM of at least five independent determinations. #P < 0.05, ###P < 0.001 vs.
control (one-way ANOVA with SCPHT).
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